Seitz R, Leugner F, Katschinski M, Immel A, Kraus M, Egbring R, Göke B
Department of Internal Medicine, Philipps University, Marburg, Germany.
Digestion. 1994;55(6):361-7. doi: 10.1159/000201166.
An important role has been ascribed to plasma factor XIII (FXIII) in inflammation and wound healing. FXIII is necessary for fibrin stabilization and interacts with connective tissue and adhesive proteins and cells. In a prospective study, FXIII activity and parameters of coagulation, fibrinolysis and inflammation, were determined in patients with ulcerative colitis (UC; 13 active, 22 moderate) and Crohn's disease (CD; 36 active, 45 moderate). FXIII levels were lower in active than in moderate UC and CD, and were < 70% of normal values in 7/13 patients with active UC, and in 7/36 patients with active CD, although the median values did not fall below the normal range. FXIII was somewhat higher in active UC patients responding to therapy. The FXIII levels were widely scattered, and low values appear to be due to greatly enhanced turnover. A correlation between FXIII and the systemic levels of markers of activation of haemostasis and inflammation was lacking, but there was a correlation with the extent of bowel involvement. FXIII levels were lower in the patients with involvement beyond the sigmoid colon in CU (p = 0.0045), and both small and large bowel segments in CD (p = 0.0223) patients. This points to local consumption and/or loss of FXIII within the inflamed tissue, and provides an argument for FXIII substitution in the treatment of acute episodes of inflammatory bowel diseases.
血浆因子 XIII（FXIII）在炎症和伤口愈合中发挥着重要作用。FXIII 对纤维蛋白稳定至关重要，并与结缔组织、黏附蛋白及细胞相互作用。在一项前瞻性研究中，对溃疡性结肠炎（UC；13 例活动期、22 例中度）和克罗恩病（CD；36 例活动期、45 例中度）患者测定了 FXIII 活性以及凝血、纤维蛋白溶解和炎症参数。活动期 UC 和 CD 患者的 FXIII 水平低于中度患者，7/13 例活动期 UC 患者和 7/36 例活动期 CD 患者的 FXIII 水平低于正常值的 70%，尽管中位数未降至正常范围以下。对治疗有反应的活动期 UC 患者的 FXIII 水平略高。FXIII 水平分布广泛，低值似乎是由于周转率大幅提高所致。FXIII 与止血和炎症激活标志物的全身水平之间缺乏相关性，但与肠道受累程度相关。在 CU 中，乙状结肠以外有受累的患者（p = 0.0045）以及 CD 患者的小肠和大肠段（p = 0.0223）中，FXIII 水平较低。这表明炎症组织内 FXIII 存在局部消耗和/或损失，并为炎症性肠病急性发作的治疗中使用 FXIII 替代疗法提供了依据。
